Tilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD Formulations

Contributed by: GlobeNewswire

Tags

Cannabis

More Like This

Tilray Expands Medical Cannabis Portfolio in Germany

Tilray Medical Granted Approval to Introduce Third Medical Cannabis Product in Portugal

Tilray Medical Announces Positive Results from Study on Oral Cannabis Extract for Chemotherapy-Induced Emesis

Tilray Medical Receives Approval for First Medical Cannabis Extract in Portugal

CBD is approved for treatment-resistant epilepsy in children, and recent trials suggest that it may be useful for treating other disorders, such as schizophrenia and anxiety. Photo credit: Julia Zolotova

Quolet announces completion of Phase 1 healthy volunteer study evaluating the safety and bioavailability of Cannabidiol in a novel formulation intended for treatment of various neurological and psychiatric diseases

Tilray Medical Supports New Clinical Trial to Study Medical Cannabis in Glioblastoma Cancer Treatment

GlobeNewswire associated0

Tilray Medical Receives Italy’s First Authorization from the Ministry of Health to Distribute Medical Cannabis Flower for Therapeutic Use

Tilray Medical Launches Tilray Craft: Introducing High THC, High Terpene Genetics to the German Medical Cannabis Market